Market cap
₹219 Cr
Revenue (TTM)
₹203 Cr
P/E Ratio
11.1
P/B Ratio
1.7
Div. Yield
0 %
| Chemkart India | JB Chemicals | Emcure Pharmaceuticals | Wockhardt | Rubicon Research | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
219 | 38,731 | 34,965 | 30,126 | 30,111 |
Revenue (₹ Cr) |
203 | 4,148 | 9,683 | 3,564 | 1,936 |
Net Profit (₹ Cr) |
24.26 | 709.47 | 1,018.97 | 414.00 | 288.22 |
Net Margin (%) |
11.81 | 16.85 | 10.47 | 11.23 | 14.79 |
RoE (%) |
58.95 | 19.11 | 21.30 | 8.38 | 29.77 |
Price to Earnings |
11.14 | 54.59 | 34.57 | 73.66 | 104.47 |
Price-To-Book |
1.69 | 9.31 | 6.68 | 5.98 | 22.43 |
Income Statement (₹ Cr)
| Chemkart India | JB Chemicals | Emcure Pharmaceuticals | Wockhardt | Rubicon Research | |
|---|---|---|---|---|---|
|
Operating Revenue
|
203.28 | 3,917.99 | 7,896.00 | 3,012.00 | 1,284.27 |
|
Total Income
|
205.46 | 3,957.03 | 7,968.78 | 3,074.00 | 1,296.22 |
|
Total Expenditure
|
170.52 | 2,886.87 | 6,427.14 | 2,619.00 | 1,028.33 |
|
EBITDA
|
32.76 | 1,031.12 | -- | 393.00 | 255.95 |
|
Depreciation
|
0.53 | 171.04 | 384.13 | 217.00 | 36.59 |
|
EBIT
|
32.23 | 860.08 | -- | 176.00 | 219.36 |
|
Interest
|
1.82 | 11.73 | 175.78 | 254.00 | 36.78 |
|
Other Income
|
2.18 | 39.04 | 72.79 | 62.00 | 11.95 |
|
Exceptional Items
|
-- | -- | -10.38 | -- | -- |
|
Profit before Tax
|
32.59 | 887.39 | 971.35 | -16.00 | 194.52 |
|
Provision for Tax
|
8.33 | 227.81 | 263.88 | 41.00 | 60.16 |
|
Profit after Tax
|
24.26 | 659.58 | 707.47 | -57.00 | 134.36 |
Liabilities (₹ Cr)
| Chemkart India | JB Chemicals | Emcure Pharmaceuticals | Wockhardt | Rubicon Research | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
53.29 | 3,433.32 | 4,446.19 | 4,353.00 | 540.98 |
|
Minority Interest
|
0.00 | -- | 195.37 | 304.00 | 0.00 |
|
Non-Current Liabilities
|
0.25 | 443.23 | 811.91 | 887.00 | 122.65 |
|
Current Liabilities
|
32.58 | 1,156.93 | 2,668.27 | 2,042.00 | 786.03 |
|
Total Liabilities
|
86.12 | 5,033.48 | -- | 8,100.00 | 1,451.43 |
Assets (₹ Cr)
| Chemkart India | JB Chemicals | Emcure Pharmaceuticals | Wockhardt | Rubicon Research | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
9.09 | 2,586.15 | 3,565.87 | 5,017.00 | 386.29 |
|
Current Assets
|
77.02 | 2,447.33 | 4,555.86 | 2,465.00 | 1,063.37 |
|
Total Assets
|
86.12 | 5,033.48 | -- | 8,100.00 | 1,451.43 |
|
Total Debt*
|
17.03 | 13.80 | 731.70 | 1,859.00 | 393.17 |
|
Net Current Assets
|
44.44 | 1,290.40 | 1,887.59 | 423.00 | 277.34 |
|
Contingent Liabilities
|
0.18 | 131.94 | 393.94 | 770.26 | 12.25 |
Cashflow (₹ Cr)
| Chemkart India | JB Chemicals | Emcure Pharmaceuticals | Wockhardt | Rubicon Research | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
3.97 | 902.45 | 851.71 | -22.00 | 159.18 |
|
Cash Flow from Investing Activities
|
-4.25 | -295.90 | -94.00 | -783.00 | -64.81 |
|
Cash from Financing Activities
|
3.05 | -579.67 | -813.96 | 409.00 | -39.81 |
|
Net Cash Inflow / Outflow
|
2.77 | 26.88 | -56.25 | -396.00 | 54.56 |
Ratios
Profitability Ratios
| Chemkart India | JB Chemicals | Emcure Pharmaceuticals | Wockhardt | Rubicon Research | |
|---|---|---|---|---|---|
|
ROCE (%)
|
61.52 | 26.73 | 22.49 | 4.07 | 26.97 |
|
ROE (%)
|
58.95 | 21.81 | 19.19 | -1.48 | 30.68 |
|
ROA (%)
|
34.75 | 13.58 | 8.94 | -0.78 | 10.50 |
|
EBIT Margin (%)
|
17.19 | 27.31 | 19.52 | 15.11 | 20.86 |
|
Net Margin (%)
|
11.81 | 16.67 | 8.88 | -1.85 | 10.37 |
|
Cash Profit Margin (%)
|
12.19 | 20.46 | 13.61 | 4.14 | 7.13 |
Growth Ratios
| Chemkart India | JB Chemicals | Emcure Pharmaceuticals | Wockhardt | Rubicon Research | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
53.97 | 12.45 | 18.59 | 7.65 | 50.40 |
|
EBIT Growth (%)
|
60.92 | 14.56 | 19.81 | 272.95 | 54.77 |
|
Net Profit Growth (%)
|
67.08 | 19.35 | 34.10 | 87.92 | 47.63 |
|
EPS Growth (%)
|
67.18 | 18.98 | 30.75 | 90.35 | 45.69 |
|
Book Value Growth (%)
|
83.65 | 17.31 | 50.94 | 29.77 | 42.49 |
Valuation Ratios
| Chemkart India | JB Chemicals | Emcure Pharmaceuticals | Wockhardt | Rubicon Research | |
|---|---|---|---|---|---|
|
Price / Earnings
|
0.00 | 38.29 | 29.84 | 0.00 | 0.00 |
|
Price / Book Value
|
0.00 | 7.73 | 4.58 | 5.31 | 0.00 |
|
Dividend Yield (%)
|
-- | 0.96 | 0.28 | 0.00 | -- |
|
EV/EBITDA
|
0.68 | 23.49 | 13.55 | 54.36 | 1.09 |
|
Market Cap (₹ Cr)
|
0.00 | 25,253.79 | 20,327.45 | 23,064.69 | 0.00 |
Solvency Ratios
| Chemkart India | JB Chemicals | Emcure Pharmaceuticals | Wockhardt | Rubicon Research | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.32 | 0.00 | 0.17 | 0.43 | 0.76 |
|
Short term debt to equity ratio
|
0.32 | 0.00 | 0.11 | 0.11 | 0.54 |
|
Current Ratio
|
2.36 | 2.12 | 1.71 | 1.21 | 1.35 |
|
Quick Ratio
|
1.67 | 1.66 | 0.98 | 0.85 | 0.69 |
|
Interest Coverage
|
18.92 | 76.66 | 6.53 | 0.94 | 6.29 |
Operating Efficiency Ratios
| Chemkart India | JB Chemicals | Emcure Pharmaceuticals | Wockhardt | Rubicon Research | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
22.53 | 20.81 | 25.36 | 21.95 | 25.21 |
|
Asset Turnover
|
2.91 | 0.84 | 1.01 | 0.53 | 1.87 |
|
Receivable days
|
69.50 | 67.54 | 87.83 | 60.36 | 47.59 |
|
Inventory Days
|
27.20 | 46.37 | 78.64 | 64.42 | 62.58 |
|
Payable days
|
22.26 | 106.33 | 174.97 | 218.94 | 228.78 |
|
Cash Conversion Cycle
|
74.43 | 7.58 | -8.50 | -94.15 | -118.62 |